Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kala Pharmaceuticals, Inc.
This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a documented clinical diagnosis of dry eye disease in both eyes
You may not be if
Known hypersensitivity or contraindication to the investigational product(s) or components
History of glaucoma, IOP\>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.
Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening.
In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.
Clareo Health | Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
